New CellaVision® DM1200 analyzer approved for sales in Canada
(Thomson Reuters ONE) - CellaVision AB (publ), which develops and sells digital morphologyproducts for the routine analysis of blood and other body fluids, hasreceived official approval for the new analyzer CellaVision® DM1200in Canada. The approval is strategically important for CellaVision'spenetration of the North American market."We have invested a large amount of resources into the studies anddocumentation necessary for selling this product on our main markets.We are now able to offer Canadian hospitals with somewhat smallertest volumes a fully automated analyzer, contributing to a moreefficient workflow at the laboratory. We are expecting this productto have a positive effect on our sales in North America," says YvonneMårtensson, CEO of CellaVision.The CellaVision DM1200 is intended to replace manual microscopy ofblood samples and is aimed at medium-sized hospital laboratories. Thedistribution between different types of white blood cells and theirappearance are important criteria in diagnosis of a number ofconditions such as infections and blood cancer. Automated technologyincreases productivity, reduces response times, and improvesdiagnostic quality.North America, including Canada, is one of CellaVision's mostimportant markets. Since 2007 CellaVision has been selling itsproducts in Canada through a subsidiary, and more than 25 analyzershave been sold to both hospital and commercial laboratories. In theUSA CellaVision sells its products both via the distributor SysmexAmerica, as well as through a subsidiary. As of 2008 North Americaaccounted for 43 percent of CellaVision's turnover.The registration was issued by the Canadian federal department HealthCanada in the end of September 2009. The product has been availableon the European market since July 2009.For more information, please contact:Yvonne Mårtensson, CEO, CellaVision ABPhone: +46 708 33 77 82. E-mail: yvonne.martensson(at)cellavision.comAbout CellaVisionCellaVision AB develops, markets, and sells market leading imageanalysis based systems for routine analysis of blood and other bodyfluids. The company has a core competence in development of softwareand hardware for automatic image analysis of cells and cell changesfor applications in health and medical care. The company develops andmarkets systems for automatic differentials of white blood cells andred morphology, and software for education and quality assurance ofdifferentials. The company's associates have expertise in advancedimaging analysis, artificial intelligence, and automated microscopy.The company headquarters are in Lund, Sweden. The company also hassubsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan.For more information, visit www.cellavision.com.CellaVision's share is listed on First North Premier at the OMXStockholm Stock Exchange. The company's Certified Advisor is RemiumAB.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 30.09.2009 - 09:01 Uhr
Sprache: Deutsch
News-ID 6406
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 323 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New CellaVision® DM1200 analyzer approved for sales in Canada"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
